Medicines Australia’s Continuing Education Program (CEP) is designed to educate medical representatives to a recognised industry standard. Dr Tristan Ling, CEP Academic Lead and Project Manager at the College of Health and Medicine, University of Tasmania talks about the 900 students that come through the program each year.
The CEP is primarily directed at medical representatives working within the prescription medicines industry, but is also recommended to people who may not be currently employed within the industry but would like to pursue a career as a medical representative. It is also available to personnel working for organisations interacting with the pharmaceutical industry.
Medicines Australia CEO Elizabeth de Somer talks about how the CEP program provides the information needed by medical representatives, that talk to health care professionals, talk with accuracy, balance and in an evidence based manner about their products.
Australian Health Journal spoke with recent CEP graduates Samantha Wicks, Christopher Lems and Megan-Anne Jefferys on their experiences in the program and how it positively impacted their confidence and knowledge of the industry.
The CEP is currently offered online through the University of Tasmania’s Unit for Medication Outcomes Research and Education (UMORE), which is housed in the University’s Pharmacy Division.
-
Interventional radiologists offer alternative to hysterectomy
In Australia in the last five years, an estimated 6066 women per year have undergone hysterectomies to treat fibroid-related diseases, while just 145 women each year have undergone a uterine artery embolisation, or UAE.
The procedure can effectively treat the majority of bleeding uterine fibroids. Each year, thousands of Australian women undergo invasive and life-altering hysterectomies to treat debilitating pain and blood loss caused by uterine fibroids. But there’s another option: a minimally invasive, pin-hole procedure that treats the symptoms, yet leaves the uterus intact.
-
Australian Teletrial Program reaches significant milestones in trials and participants
Launched in 2022, the Australian Teletrial Program is an initiative designed to improve access to clinical trials for people living in regional and remote areas of Australia. It uses telemedicine and digital technologies to enable patients to participate in clinical trials without needing to travel long distances to major metropolitan centres, which can often be a barrier to participation for those in rural and isolated locations.
Recently Australian Health Journal met with Kaye Hewson, Director, Australian Teletrials Program, who spoke about the program’s recent achievements.
-
Improvements in dental literacy and greater clinical insights through digital technology
Dr. Kenneth Soh is a General Dentist based in Kellyville, New South Wales, a suburb located in northwestern Sydney. Originally from Melbourne, he studied Bachelor of Dental Science (BDSc) at Melbourne University and graduated in 2003. After working for a year in the Mornington Peninsula, Dr. Soh moved to New South Wales, initially thinking it would be temporary; however, he has been there for 19 years. While he has considered specialising, he finds joy in all aspects of dentistry.
